Most U.S. states do not currently cover highly sought-after weight-loss drugs from Novo Nordisk and Eli Lilly in their Medicaid health programs for low-income people, citing cost as a key factor, according to a survey.
<p>NEW YORK — Most U.S.
</p><p>The drugs from a class known as GLP-1 agonists were initially developed to treat Type 2 diabetes but also promote weight loss by suppressing hunger.
Traffic Weather Sports Classifieds Cars Jobs Homes Television Radio Salt Lake Utah Local
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ozempic, Wegovy maker Novo Nordisk faces hearing over high cost of weight loss drugsBlockbuster drugs Ozempic and Wegovy have sparked conversation and changed weight loss worldwide. In an exclusive interview, NBC News’ Megan Fitzgerald sits down with Novo Nordisk CEO Lars Fruergaard Jørgensen who helmed it all, and presses him on the high price, drug shortages, and long-term effects.
Read more »
Novo Nordisk CEO to testify at Senate hearing over high weight loss drug pricesSen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for patients in other countries.
Read more »
Novo Nordisk CEO to Face Senate Grilling Over High Drug PricesThe CEO of Novo Nordisk, Lars Fruergaard Jørgensen, will testify before the Senate Health, Education, Labor and Pensions Committee on Tuesday regarding the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic. Sen. Bernie Sanders, who chairs the committee, alleges that Novo Nordisk charges significantly higher prices for its drugs in the US compared to other countries.
Read more »
Novo Nordisk CEO testifies at Senate hearing over high weight loss drug pricesSen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for patients in other countries.
Read more »
Novo Nordisk CEO Claims High Drug Prices Due to US Healthcare SystemNovo Nordisk CEO Lars Fruergaard Jørgensen faced questioning on Capitol Hill over the high cost of the company's weight-loss drugs, Ozempic and Wegovy. Jørgensen claimed the high prices were due to complications of the U.S. healthcare system.
Read more »
Ozempic maker Novo Nordisk testifies before Senate committee on weight loss drug pricesNovo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on Tuesday.
Read more »